Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vical receives safety recommendation

VICL said a Drug Safety Review Board (DSRB) recommended that its Phase II and Phase III trials of Allovectin-7 gene therapy to

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE